Simultaneous Determination of a Novel PD-L1 Inhibitor, IMMH-010, and Its Active Metabolite, YPD-29B, in Rat Biological Matrices by Polarity-Switching Liquid Chromatography-Tandem Mass Spectrometry: Application to ADME Studies

Jianwei Jiang, Xiaowen Zou, Yuke Liu, Xiao Liu, Kai Dong, Xiaoqing Yao, Zhiqiang Feng, Xiaoguang Chen, Sheng Li, Li YanFrontiers in Pharmacology 2021 · DOI

Introduction

Cancer immunotherapy has been revolutionized by PD-L1 checkpoint inhibitors, though most current treatments are monoclonal antibodies requiring intravenous administration. IMMH-010 is a novel small-molecule prodrug designed to overcome these limitations through oral delivery. Upon administration, IMMH-010 is rapidly converted into its active metabolite, YPD-29B. Characterizing the Absorption, Distribution, Metabolism, and Excretion (ADME) profile of this drug candidate is critical for its clinical progression.

Analytical Methodology

A significant challenge in analyzing IMMH-010 and YPD-29B simultaneously is their differing chemical properties; the prodrug ionizes most efficiently in positive mode, whereas the metabolite prefers negative mode. To address this, researchers developed a high-efficiency Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) method utilizing rapid polarity switching.

The method employs a Zorbax SB-C18 column for separation and a stabilized protocol using sodium fluoride (NaF) to prevent prodrug degradation in biological samples. The mass spectrometer is programmed to detect YPD-29B in negative ion mode during the initial phase of the run, followed by an instantaneous switch to positive ion mode for IMMH-010 detection. This unified approach reduces analysis time and sample volume by 50% compared to traditional dual-method strategies.

Mass spectra illustrating the polarity-switching approach. Panels A and B display the precursor and product ions for IMMH-010 in positive mode, while C and D show the corresponding scans for YPD-29B in negative mode.

Pharmacokinetic and Tissue Distribution Results

Pharmacokinetic studies in Sprague-Dawley rats demonstrated that IMMH-010 is a highly effective prodrug, undergoing rapid and extensive conversion to YPD-29B. Both compounds reached peak plasma concentrations ($C_{max}$) within 0.5 to 1 hour. Within the 10–100 mg/kg dose range, the drug exhibited linear kinetics, with internal exposure (AUC) increasing proportionally to the dose.

Tissue distribution analysis revealed significant localization in the lymphatic system. IMMH-010 was primarily found in the adrenal glands, lymph nodes, heart, liver, and spleen. YPD-29B was predominantly observed in the liver, lymph nodes, kidneys, and lungs. This high distribution in lymphatic tissues is particularly advantageous for immunotherapy, as these are primary sites for immune cell trafficking.

Excretion and Mass Balance

The study tracked drug recovery over a 72-hour period, finding that approximately 28.81% of the administered dose was recovered in urine and feces. Fecal excretion was the dominant pathway, with the active metabolite YPD-29B accounting for 20.82% of the total dose and unchanged IMMH-010 accounting for 7.99%. The relatively low total recovery suggests the presence of additional metabolites not captured by the current method, indicating a need for broader metabolic profiling in future studies.

Conclusion

The developed polarity-switching LC-MS/MS method provides a robust and sensitive tool for the simultaneous quantification of IMMH-010 and YPD-29B. The resulting ADME data supports the further development of IMMH-010 as a promising oral PD-L1 inhibitor, with favorable lymphatic targeting and predictable pharmacokinetic behavior.

Clinical Trial Registration: NCT04343859

Summary updated

Abstract

IMMH-010 is a prodrug of YPD-29B, which is a novel PD-L1 inhibitor. A specific and sensitive LC-MS/MS method with polarity switching was developed and validated for the simultaneous determination of IMMH-010 and YPD-29B in rat plasma, liver, brain, urine and fecal samples. Method validation was investigated to demonstrate the lower limit of quantification linearity, precision and accuracy, matrix effect and recovery, stability and dilution reliability for IMMH-010 and YPD-29B. This validated method was successfully applied to investigate the pharmacokinetics, tissue distribution, and excretion of IMMH-010 and YPD-29B in rats. After oral administration of IMMH-010 maleate to rats, IMMH-010 was rapidly and extensively converted to the active metabolite YPD-29B. The areas under the plasma concentration-time curve (AUC) of IMMH-010 and YPD-29B were proportional to the dose in the range of 10-100 mg/kg. IMMH-010 was primarily distributed in the adrenal gland, lymph nodes, heart, liver and spleen. YPD-29B was mainly observed in the liver, lymph, kidney, and lung. Approximately 28.81% of the IMMH-010 dose was recovered in the urine and feces within 72 h, including unchanged IMMH-010 (7.99%) and YPD-29B (20.82%). The results of this study may be useful as a reference for further development of IMMH-010 and PD-L1 inhibitors. <b>Clinical Trial Registration</b>: [https://clinicaltrials.gov/ct2/show/NCT04343859?term=IMMH-010&draw=2&rank=1], identifier [NCT04343859]."
BibTeX
@inproceedings{jiang2021simultaneous,
  author = {Jianwei Jiang and Xiaowen Zou and Yuke Liu and Xiao Liu and Kai Dong and Xiaoqing Yao and Zhiqiang Feng and Xiaoguang Chen and Sheng Li and Li Yan},
  title = {{Simultaneous Determination of a Novel PD-L1 Inhibitor, IMMH-010, and Its Active Metabolite, YPD-29B, in Rat Biological Matrices by Polarity-Switching Liquid Chromatography-Tandem Mass Spectrometry: Application to ADME Studies}},
  booktitle = {Frontiers in Pharmacology},
  year = {2021},
  doi = {10.3389/fphar.2021.677120},
}
Figure